Navigation Links
Parkinson's Treatment Drugs Even Out Over Long Term

Levels of disability, quality of life similar on levodopa or pramipexole, study finds

WEDNESDAY, March 11 (HealthDay News) -- Two drugs -- levodopa and pramipexole -- used to treat early stage Parkinson's disease each have advantages and disadvantages, but their overall impact appears to even out over a long period of treatment.

That's the conclusion of a new study that included hundreds of patients in Canada and the United States.

"Clinicians and patients often struggle with what is the right initial approach to treating Parkinson's disease. This study tells us that, over the long haul, patients on the different drugs end up at roughly the same place in terms of their level of disability and quality of life," lead author Dr. Kevin Biglan, a neurologist at the University of Rochester Medical Center in New York, said in a school news release.

The two drugs use different mechanisms to counteract the decline in the production of dopamine in the brain that causes Parkinson's symptoms. Levodopa is an amino acid that the body metabolizes into dopamine. Pramipexole binds with dopamine receptors on cells in the brain and mimics dopamine's molecular function.

Levodopa is considered better at treating motor control problems in Parkinson's patients but is also associated with side effects such as dyskinesia (involuntary movements), and the effectiveness of the drug can wear off over time. Pramipexole is less commonly associated with dyskinesea and wearing off, but is less effective in treating motor control problems and more often causes sleepiness, according to background information in the news release.

Doctors often prescribe pramipexole first, because it extends the length of time a patient can benefit from levodopa before its effect wears off.

The initial study included 301 patients at 22 sites who were followed for two years. A subset of 222 of those patients was followed for an additional four years. At the start of the study, half the patients were randomly selected to receive levodopa and half to receive pramipexole. After six years of follow-up, 90 percent of patients were taking levodopa.

Patients initially treated with levodopa were more likely to develop motor control complications such as dyskinesia and wearing off, but these complications didn't have a significant impact on patients' quality of life or disability, the researchers found.

The study, published online March 9 in the journal Archives of Neurology, was funded by Pharmacia Corp. and Boehringer Ingelheim.

More information

We Move has more about Parkinson's disease.

-- Robert Preidt

SOURCE: University of Rochester Medical Center, news release, March 9, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
Related Image:
Parkinson's Treatment Drugs Even Out Over Long Term
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: